

IPOs

The following table includes the medical devices, biotechnology, pharmaceuticals, and healthcare IPO pricings, filings and withdrawals announced over the previous week. Dollars (\$) are expressed in millions.

Date	Company	Ticker	Description	Size	Lead Manager
29-Jan-10	BG Medicine	BGMD	BG Medicine is a Waltham, MA-based provider of molecular diagnostics based on biomarkers.	\$86.25 million.	Jefferies & Co., UBS.

Private Equity Placements and Venture Capital Rounds

The following table includes institutionally placed private equity financings for private and public medical devices, biotechnology, pharmaceuticals, and healthcare companies

Date	Company	Round	Description	Size	Lead Investors
31-Dec-09	Synapse Biomedical Inc.	Later	Synapse Biomedical Inc. is an Oberlin, OH-based developer of minimally invasive neurostimulation devices for the diagnosis and treatment of neurodegenerative disease.	\$0.43 million.	Undisclosed.
5-Jan-10	CardioInsight Technologies Inc.	B	CardioInsight Technologies Inc. is a Cleveland, OH-based developer of non-invasive electrocardiographic imaging technology.	\$5.74 million.	Undisclosed.
20-Jan-10	U.S. HealthWorks Medical Group	Later	U.S. HealthWorks Medical Group is a Valencia, CA-based provider of occupational healthcare services to large and small employers in a range of industries.	\$25.00 million.	Altaris Health Partners, Management, Three Arch Partners.
21-Jan-10	Cellular Dynamics International Inc.	C	Cellular Dynamics International Inc. is a Madison, WI-based developer of stem cell technologies for drug development and personalized medicine.	\$31.25 million.	Undisclosed.
22-Jan-10	Foundation Radiology Group	B	Foundation Radiology Group is a Pittsburgh, PA-based provider of diagnostic imaging professional services to hospitals, outpatient imaging centers, urgent care centers, and long-term acute care institutions.	\$4.50 million.	Undisclosed.
25-Jan-10	Intercept Pharmaceuticals	B	Intercept Pharmaceuticals is a New York, NY-based developer of small molecule drugs for the treatment of chronic liver and metabolic diseases.	\$25.00 million.	Genextra.
26-Jan-10	Cornerstone Pharmaceuticals	B	Cornerstone Pharmaceuticals is a Cranbury, NJ-based developer of cancer therapeutics.	\$6.18 million.	C.W. Downer & Co., Althea Partners.
26-Jan-10	Eribis Pharmaceuticals AB	A	Eribis Pharmaceuticals AB is an Uppsala, Sweden-based developer of drugs for the treatment of cardiovascular disorders, in particular acute myocardial ischemia, and also for surgical preconditioning.	Undisclosed.	Karolinska Development AB.
26-Jan-10	Imperative Health	B	Imperative Health is a London, UK-based provider of technology solutions for personalized weight management.	\$4.00 million.	New Venture Partners LLC, Unilever Ventures.

27-Jan-10	Juvaris BioTherapeutics Inc.	B	Juvaris BioTherapeutics Inc. is a Burlingame, CA-based developer of adjuvanted vaccines and immunotherapeutics to treat infectious diseases and cancer.	\$25.00 million.	SV Life Sciences, Kleiner, Perkins, Caufield & Byers.
27-Jan-10	NeoMend Inc.	C	NeoMend Inc. is an Irvine, CA-based developer of surgical wound healing products.	\$30.00 million.	Clarus Ventures, Novo, Prospect Venture Partners, Sanderling Ventures, Vivo Ventures.
28-Jan-10	Alnara Pharmaceuticals, Inc.	B	Alnara Pharmaceuticals, Inc. is a Cambridge, MA-based developer of non-systemic protein therapeutics for the treatment of metabolic and inflammatory diseases.	\$35.00 million.	MPM Capital, Bessemer Venture Partners, Frazier Healthcare Ventures, Third Rock Ventures.
28-Jan-10	Rapid Diagnostek	B	Rapid Diagnostek is a Hudson, WI-based developer of a sensor for detecting bacteria, viruses, spores, and disease biomarkers.	\$1.50 million.	Peak Ridge Capital.
29-Jan-10	Flexion Therapeutics Inc.	A-2	Flexion Therapeutics Inc. is a Woburn, MA-based provider of a vehicle to define the potential of drug candidates, advance candidates of demonstrated potential through commercialization, and optimize portfolio value.	\$9.00 million.	Pfizer Venture Capital Group.
29-Jan-10	Merus B.V.	B	Merus B.V. is a Utrecht, Netherlands-based developer of human antibodies.	\$30.31 million.	The Novartis Option Fund, Pfizer, Bay City Capital, Life Sciences Partners, Aglaia Oncology Fund.

Mergers and Acquisitions

The following table includes mergers and acquisitions for private and public medical devices, biotechnology, pharmaceuticals, and healthcare companies announced over the

Date	Acquiror	Target	Description	Transaction Value
27-Jan-10	Ligand Pharmaceuticals Inc.	Metabasis Therapeutics	Metabasis Therapeutics is a San Diego, CA-based developer of novel small-molecule drugs to treat metabolic diseases linked to pathways in the liver, and to treat liver diseases.	Undisclosed.

Compiled by: Ryan Barrett

Sources: Venture Wire, Private Equity Week, Wall Street Journal, Venture Source, SEC Filings, Company press releases, and www.biospace.com